Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60004 | 0.77 | RAD52 (0.55) | KDM1ARAD52HDAC9MEN1KMT2A | |
| SCHEMBL29677121 | 0.77 | KDM4E (0.45) | KDM1AHDAC9MEN1KMT2A | |
| SCHEMBL5310777 | 0.77 | KDM4E (0.45) | KDM1AHDAC9MEN1KMT2A | |
| Phenylethyl Alcohol SCHEMBL7644433 | 0.77 | SIGMAR1 (0.44) | KDM1ARAD52MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11149959 | 0.76 | RAD52 (0.53) | KDM1ARAD52HDAC9MEN1KMT2A | |
| SCHEMBL9433786 | 0.72 | KDM1A (0.49) | KDM1AHDAC9MEN1KMT2AAKR1B1 | |
| Hydrochloric Acid SCHEMBL11788510 | 0.72 | KDM1A (0.47) | KDM1ACASP6RAD52HDAC9MEN1 | |
| SCHEMBL28136912 | 0.70 | KDM1A (0.45) | KDM1AHDAC9MEN1KMT2AKIF11 | |
| SCHEMBL15848044 | 0.70 | KDM1A (0.53) | KDM1AHDAC9MEN1KMT2AAKR1B1 | |
| SCHEMBL1593168 | 0.70 | KDM1A (0.38) | KDM1ACASP6RAD52HDAC9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092509-A1 | Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction | Kissei Pharmaceutical, Co. Ltd. (JP) | 2011-04-21 | — | — | US | disclosed |
| JP-2002302464-A | OPTICALLY ACTIVE HALOHYDRIN DERIVATIVE AND USE THEREOF | KISSEI PHARMACEUT CO LTD | 2002-10-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092509-A1 | Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction | SSB, CUTA, HRH2 | KDM1A 2615/4885CASP6 2169/4885RAD52 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.